Two new measures tied to outcomes drawn from data in the CLEAR phase 3 trial will be presented during the ASCO Genitourinary ...

The differential diagnoses for CRCC include RCC with cystic change, hereditary leiomyomatosis manifesting as a cystic renal lesion, cystic nephroma, clear ... Cystic renal cell carcinoma is ...

In a clinical trial, patients treated with a kidney cancer vaccine remained cancer-free after a median of nearly three years.

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Over the past 5 years, targeted therapy has significantly impacted on metastatic renal cell carcinoma (mRCC ... At present, there is no clear evidence of superiority of either sequence (TKI ...

A neoantigen-targeting personalized cancer vaccine may be effective as adjuvant therapy in patients with high-risk clear cell renal cell carcinoma, phase 1 data suggest.

A highly vascularized cancer that is especially reliant on tumor endothelial cells is clear cell renal cell carcinoma (ccRCC). Almost 80% of malignant tumors in the kidney are ccRCC, and the 5-year ...

Neoantigen-targeting personalized cancer vaccines (PCVs) are highly immunogenic in high-risk clear cell renal cell ca ...

Researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a successful anti-cancer immune ...

Dana-Farber Cancer Institute researchers report that all nine patients in a clinical trial being treated for stage III or IV clear cell renal cell carcinoma (a form of kidney cancer), generated a ...